BioCentury | Aug 29, 2020
Product Development

COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent

...Inc. Abbott Laboratories CanSino Biologics Inc. BeiGene Ltd. Sinovac Biotech Ltd. University of North Carolina at Chapel Hill Daiichi Sankyo Co. Ltd. Laurent Pharmaceuticals Inc. Interferon...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

...The CFF also is funding clinical trials of two less advanced anti-inflammatory agents. One is Laurent Pharmaceuticals Inc.’s...
...Fibrosis Foundation, Bethesda, Md. Cystic Fibrosis Trust, London, U.K. European Cystic Fibrosis Society, Karup, Denmark Laurent Pharmaceuticals Inc....
BioCentury | Apr 13, 2017
Targets & Mechanisms

Cool and also collected

...alone and in combination with lumacaftor -- a corrector -- under the name Orkambi ivacaftor/lumacaftor. Laurent Pharmaceuticals Inc....
...to disclose the next steps. Companies and Institutions Mentioned The George Washington University, Washington, D.C. Laurent Pharmaceuticals Inc....
...α1 represents a potential potent single-molecule-based therapy for cystic fibrosis." Nature Medicine (2017) Karen Tkach, Senior Writer Laurent Pharmaceuticals Inc. San...
BioCentury | Mar 21, 2016
Financial News

Laurent Pharmaceuticals completes venture financing

Laurent Pharmaceuticals Inc. , Montreal, Quebec Business: Pulmonary Date completed: 2016-03-17 Type: Venture financing Raised: Not disclosed Investors: Cystic Fibrosis Canada; Aligo Innovation; Anges Quebec; existing investors; private investors Note: The amount raised is not disclosed....
BioCentury | Sep 14, 2015
Product Development

Balancing act

...responsible for aberrant mucus buildup in the airways, but mucus is only half the problem. Laurent Pharmaceuticals Inc....
...of use patents for fenretinide, which include its use in CF. Companies and Institutions Mentioned Laurent Pharmaceuticals Inc....
BioCentury | Jul 20, 2015
Clinical News

LAU-7b: Phase Ib data

...showed that once-daily 100, 200 and 300 mg doses of oral LAU-7b were well tolerated. Laurent Pharmaceuticals Inc....
Items per page:
1 - 6 of 6
BioCentury | Aug 29, 2020
Product Development

COVID-19 Quick Takes: FDA expands remdesivir EUA; plus Warp Speed, Abbott, Moderna-Japan, CanSino-Canada, BeiGene-Singlomics, Sinovac, UNC, Daiichi, Laurent

...Inc. Abbott Laboratories CanSino Biologics Inc. BeiGene Ltd. Sinovac Biotech Ltd. University of North Carolina at Chapel Hill Daiichi Sankyo Co. Ltd. Laurent Pharmaceuticals Inc. Interferon...
BioCentury | Aug 11, 2018
Product Development

Exacerbation management

...The CFF also is funding clinical trials of two less advanced anti-inflammatory agents. One is Laurent Pharmaceuticals Inc.’s...
...Fibrosis Foundation, Bethesda, Md. Cystic Fibrosis Trust, London, U.K. European Cystic Fibrosis Society, Karup, Denmark Laurent Pharmaceuticals Inc....
BioCentury | Apr 13, 2017
Targets & Mechanisms

Cool and also collected

...alone and in combination with lumacaftor -- a corrector -- under the name Orkambi ivacaftor/lumacaftor. Laurent Pharmaceuticals Inc....
...to disclose the next steps. Companies and Institutions Mentioned The George Washington University, Washington, D.C. Laurent Pharmaceuticals Inc....
...α1 represents a potential potent single-molecule-based therapy for cystic fibrosis." Nature Medicine (2017) Karen Tkach, Senior Writer Laurent Pharmaceuticals Inc. San...
BioCentury | Mar 21, 2016
Financial News

Laurent Pharmaceuticals completes venture financing

Laurent Pharmaceuticals Inc. , Montreal, Quebec Business: Pulmonary Date completed: 2016-03-17 Type: Venture financing Raised: Not disclosed Investors: Cystic Fibrosis Canada; Aligo Innovation; Anges Quebec; existing investors; private investors Note: The amount raised is not disclosed....
BioCentury | Sep 14, 2015
Product Development

Balancing act

...responsible for aberrant mucus buildup in the airways, but mucus is only half the problem. Laurent Pharmaceuticals Inc....
...of use patents for fenretinide, which include its use in CF. Companies and Institutions Mentioned Laurent Pharmaceuticals Inc....
BioCentury | Jul 20, 2015
Clinical News

LAU-7b: Phase Ib data

...showed that once-daily 100, 200 and 300 mg doses of oral LAU-7b were well tolerated. Laurent Pharmaceuticals Inc....
Items per page:
1 - 6 of 6